Who Paid My Doc
Parsabiv
Drug Nephrology
NDC 55513-740-10
General payments
$1,182,332
Research payments
$764,000
Through program year 2025, $1,182,332 in general payments and $764,000 in research payments were reported against Parsabiv (Nephrology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
13 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $502 | 7 |
| 2025 | Research | $85,083 | 12 |
| 2024 | General | $72,536 | 1,752 |
| 2024 | Research | $150,199 | 15 |
| 2023 | General | $106,582 | 2,225 |
| 2023 | Research | $154,922 | 6 |
| 2022 | General | $301,244 | 5,585 |
| 2022 | Research | $51,178 | 4 |
| 2021 | General | $422,220 | 6,766 |
| 2021 | Research | $123,363 | 12 |
| 2020 | General | $277,086 | 3,394 |
| 2020 | Research | $199,254 | 45 |
| 2019 | General | $2,161 | 101 |
Breakdown
The top 5 of 6 recipients; each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
19,830 general · 94 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.